Details of the Drug

General Information of Drug (ID: DMJV2EK)

Drug Name
Dasatinib
Synonyms
Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
Indication
Disease Entry ICD 11 Status REF
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive N.A. Approved [1]
Brain disease 8C70-8E61 Approved [1]
Central nervous system disease 8A04-8D87 Approved [1]
Chronic myelogenous leukaemia 2A20.0 Approved [2]
Chronic myeloid leukaemia 2A20 Approved [3]
Glioblastoma 2A00 Approved [1]
Leukemia N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Multiple myeloma 2A83 Phase 2 [2]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [4]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [4]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 488
Logarithm of the Partition Coefficient (xlogp) 3.6
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Elimination
0.1% of drug is excreted from urine in the unchanged form [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.8546 micromolar/kg/day [6]
Chemical Identifiers
Formula
C22H26ClN7O2S
IUPAC Name
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
Canonical SMILES
CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
InChI
InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
InChIKey
ZBNZXTGUTAYRHI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3062316
ChEBI ID
CHEBI:49375
CAS Number
302962-49-8
DrugBank ID
DB01254
TTD ID
D0E6XR
VARIDT ID
DR00182
INTEDE ID
DR0423
ACDINA ID
D00171
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Inhibitor [7]
Fyn tyrosine protein kinase (FYN) TT2B9KF FYN_HUMAN Inhibitor [7]
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [7]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [7]
HUMAN fusion protein Bcr-Abl (Bcr-Abl) TTE63HY BCR_HUMAN/ABL1_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [9]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Dimethylaniline oxidase 3 (FMO3) DEP76YL FMO3_HUMAN Substrate [12]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Gene/Protein Processing [13]
5-hydroxytryptamine receptor 2B (HTR2B) OTM1AD9J 5HT2B_HUMAN Gene/Protein Processing [13]
A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) OT953SV2 ATS5_HUMAN Gene/Protein Processing [13]
Abnormal spindle-like microcephaly-associated protein (ASPM) OTKXQMNA ASPM_HUMAN Gene/Protein Processing [13]
Actin, alpha cardiac muscle 1 (ACTC1) OTJU04B1 ACTC_HUMAN Gene/Protein Processing [13]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Gene/Protein Processing [13]
Actin, gamma-enteric smooth muscle (ACTG2) OTRDWUO0 ACTH_HUMAN Gene/Protein Processing [13]
Adenylate kinase isoenzyme 5 (AK5) OTTGXLOT KAD5_HUMAN Gene/Protein Processing [13]
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) OTG0TTX7 CD38_HUMAN Gene/Protein Processing [14]
Aggrecan core protein (ACAN) OTUOCW8K PGCA_HUMAN Gene/Protein Processing [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dasatinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Dasatinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [15]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Dasatinib and Nilotinib. Myeloproliferative neoplasm [2A20] [16]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Dasatinib and Ruxolitinib. Myeloproliferative neoplasm [2A20] [15]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Dasatinib and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [17]
Coadministration of a Drug Treating the Disease Different from Dasatinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Dasatinib due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [15]
Metreleptin DM1NOEK Moderate Increased metabolism of Dasatinib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [18]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Dasatinib and Ivosidenib. Acute myeloid leukaemia [2A60] [19]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Midostaurin. Acute myeloid leukaemia [2A60] [15]
Arn-509 DMT81LZ Major Increased metabolism of Dasatinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [18]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Gilteritinib. Acute myeloid leukaemia [2A60] [20]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Oliceridine. Acute pain [MG31] [15]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Dasatinib and Ivabradine. Angina pectoris [BA40] [21]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Dasatinib and Dronedarone. Angina pectoris [BA40] [16]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Dasatinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [22]
Posaconazole DMUL5EW Major Decreased metabolism of Dasatinib caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [18]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Levalbuterol. Asthma [CA23] [23]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Dasatinib and Roflumilast. Asthma [CA23] [21]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [21]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Dasatinib caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [18]
Troleandomycin DMUZNIG Major Decreased metabolism of Dasatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [18]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Retigabine. Behcet disease [4A62] [15]
Cariprazine DMJYDVK Moderate Decreased metabolism of Dasatinib caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [21]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Dasatinib caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [18]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Eribulin. Breast cancer [2C60-2C6Y] [16]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Dasatinib caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Lapatinib. Breast cancer [2C60-2C6Y] [15]
LY2835219 DM93VBZ Moderate Decreased metabolism of Dasatinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Tucatinib DMBESUA Major Decreased metabolism of Dasatinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Palbociclib DMD7L94 Moderate Decreased metabolism of Dasatinib caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [21]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Dasatinib caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Dasatinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Bosutinib DMTI8YE Moderate Decreased metabolism of Dasatinib caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [21]
Trastuzumab Emtansine DMU1LXS Major Increased risk of bleeding by the combination of Dasatinib and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [18]
Macitentan DMP79A1 Moderate Decreased metabolism of Dasatinib caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [26]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [27]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [28]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [23]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Indacaterol. Chronic obstructive pulmonary disease [CA22] [28]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Arformoterol. Chronic obstructive pulmonary disease [CA22] [28]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Dasatinib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [18]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Dasatinib and Regorafenib. Colorectal cancer [2B91] [15]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Probucol. Coronary atherosclerosis [BA80] [15]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Dasatinib and Ardeparin. Coronary thrombosis [BA43] [15]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Dasatinib and Pasireotide. Cushing syndrome [5A70] [16]
Lumacaftor DMCLWDJ Major Increased metabolism of Dasatinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [18]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Dasatinib caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [29]
MK-8228 DMOB58Q Moderate Decreased metabolism of Dasatinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [15]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Dasatinib and Danaparoid. Deep vein thrombosis [BD71] [15]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Dasatinib and Rivaroxaban. Deep vein thrombosis [BD71] [15]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Dasatinib and Vilazodone. Depression [6A70-6A7Z] [30]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Dasatinib and Vortioxetine. Depression [6A70-6A7Z] [30]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Dasatinib and Milnacipran. Depression [6A70-6A7Z] [30]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Dasatinib and Desvenlafaxine. Depression [6A70-6A7Z] [30]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Dasatinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [31]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Dasatinib and Heme. Discovery agent [N.A.] [32]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Dasatinib caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [18]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Dasatinib due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [15]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Dasatinib and Apigenin. Discovery agent [N.A.] [33]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [16]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Ingrezza. Dystonic disorder [8A02] [34]
Cenobamate DM8KLU9 Moderate Increased metabolism of Dasatinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Fosphenytoin DMOX3LB Major Increased metabolism of Dasatinib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Dasatinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Dasatinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [35]
Tazemetostat DMWP1BH Moderate Decreased metabolism of Dasatinib caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [36]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Solifenacin. Functional bladder disorder [GC50] [15]
Mirabegron DMS1GYT Minor Decreased metabolism of Dasatinib caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [37]
Dexlansoprazole DM1DBV5 Major Decreased absorption of Dasatinib due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [15]
Ripretinib DM958QB Moderate Decreased metabolism of Dasatinib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [18]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Sunitinib. Gastrointestinal stromal tumour [2B5B] [15]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Dasatinib and Avapritinib. Gastrointestinal stromal tumour [2B5B] [15]
Colchicine DM2POTE Moderate Decreased metabolism of Dasatinib caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [15]
Boceprevir DMBSHMF Major Decreased metabolism of Dasatinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [15]
Telaprevir DMMRV29 Major Decreased metabolism of Dasatinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [18]
MK-1439 DM215WE Minor Decreased metabolism of Dasatinib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Dasatinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [39]
Cobicistat DM6L4H2 Major Decreased metabolism of Dasatinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Dolutegravir DMCZGRE Minor Decreased metabolism of Dasatinib caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Etravirine DMGV8QU Moderate Increased metabolism of Dasatinib caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [41]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [15]
Darunavir DMN3GCH Major Decreased metabolism of Dasatinib caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Maraviroc DMTL94F Moderate Decreased clearance of Dasatinib due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [42]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Dasatinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [43]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Dasatinib caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [44]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Dasatinib due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [21]
Retapamulin DM9JXB7 Minor Decreased metabolism of Dasatinib caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [45]
Lesinurad DMUR64T Moderate Increased metabolism of Dasatinib caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [18]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Dasatinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [15]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Dasatinib caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [18]
Amobarbital DM0GQ8N Moderate Increased metabolism of Dasatinib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [18]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [21]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Dasatinib and Phenolphthalein. Irritable bowel syndrome [DD91] [16]
Naloxegol DML0B41 Minor Decreased metabolism of Dasatinib caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [46]
Pemigatinib DM819JF Moderate Decreased metabolism of Dasatinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [21]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Dasatinib caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [18]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Dasatinib and Denosumab. Low bone mass disorder [FB83] [47]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Dasatinib and Crizotinib. Lung cancer [2C25] [48]
Brigatinib DM7W94S Moderate Increased metabolism of Dasatinib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [18]
Ceritinib DMB920Z Major Decreased metabolism of Dasatinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [18]
PF-06463922 DMKM7EW Moderate Increased metabolism of Dasatinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [18]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Dasatinib and Osimertinib. Lung cancer [2C25] [49]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Dasatinib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [50]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Dasatinib and Selpercatinib. Lung cancer [2C25] [21]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Dasatinib and Hydroxychloroquine. Malaria [1F40-1F45] [51]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [21]
Idelalisib DM602WT Major Decreased metabolism of Dasatinib caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [18]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Dasatinib caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [18]
IPI-145 DMWA24P Moderate Decreased metabolism of Dasatinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [15]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Dasatinib and Acalabrutinib. Mature B-cell lymphoma [2A85] [15]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Dasatinib and Ibrutinib. Mature B-cell lymphoma [2A85] [15]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Dasatinib and Ponatinib. Mature B-cell lymphoma [2A85] [15]
Arry-162 DM1P6FR Major Increased risk of bleeding by the combination of Dasatinib and Arry-162. Melanoma [2C30] [15]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Dasatinib and Vemurafenib. Melanoma [2C30] [16]
Selumetinib DMC7W6R Moderate Decreased metabolism of Dasatinib caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [52]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and LGX818. Melanoma [2C30] [53]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Dasatinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [21]
Danazol DML8KTN Moderate Decreased metabolism of Dasatinib caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [15]
Flibanserin DM70DTN Moderate Decreased metabolism of Dasatinib caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [54]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Dasatinib and Panobinostat. Multiple myeloma [2A83] [55]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Dasatinib and Tecfidera. Multiple sclerosis [8A40] [56]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Dasatinib and Siponimod. Multiple sclerosis [8A40] [18]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Dasatinib and Fingolimod. Multiple sclerosis [8A40] [57]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Dasatinib and Ozanimod. Multiple sclerosis [8A40] [21]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Romidepsin. Mycosis fungoides [2B01] [15]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Dasatinib and Prasugrel. Myocardial infarction [BA41-BA43] [15]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Entrectinib. Non-small cell lung cancer [2C25] [18]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Lofexidine. Opioid use disorder [6C43] [16]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Dasatinib and Nepafenac. Osteoarthritis [FA00-FA05] [58]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Rucaparib. Ovarian cancer [2C73] [15]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Triclabendazole. Parasitic worm infestation [1F90] [15]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Pimavanserin. Parkinsonism [8A00] [59]
Abametapir DM2RX0I Moderate Decreased metabolism of Dasatinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [60]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Dasatinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [61]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Dasatinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [18]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Degarelix. Prostate cancer [2C82] [21]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Dasatinib and ABIRATERONE. Prostate cancer [2C82] [21]
Enzalutamide DMGL19D Major Increased metabolism of Dasatinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [18]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Relugolix. Prostate cancer [2C82] [21]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Levomepromazine. Psychotic disorder [6A20-6A25] [15]
Everolimus DM8X2EH Moderate Decreased metabolism of Dasatinib caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [62]
Axitinib DMGVH6N Moderate Decreased metabolism of Dasatinib caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [21]
Temsirolimus DMS104F Moderate Decreased metabolism of Dasatinib caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [63]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Dasatinib and Canakinumab. Rheumatoid arthritis [FA20] [64]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Dasatinib and Rilonacept. Rheumatoid arthritis [FA20] [64]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Dasatinib and Golimumab. Rheumatoid arthritis [FA20] [65]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Dasatinib and Iloperidone. Schizophrenia [6A20] [16]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Paliperidone. Schizophrenia [6A20] [15]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Dasatinib and Amisulpride. Schizophrenia [6A20] [66]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Asenapine. Schizophrenia [6A20] [16]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Dasatinib when combined with Anthrax vaccine. Sepsis [1G40-1G41] [67]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Dasatinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [15]
LDE225 DMM9F25 Moderate Decreased metabolism of Dasatinib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [68]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Dasatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [18]
Larotrectinib DM26CQR Moderate Decreased metabolism of Dasatinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [18]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Dasatinib caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [21]
Armodafinil DMGB035 Moderate Increased metabolism of Dasatinib caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [18]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Dasatinib and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [16]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [21]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Pitolisant. Somnolence [MG42] [18]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [15]
Plicamycin DM7C8YV Major Increased risk of bleeding by the combination of Dasatinib and Plicamycin. Testicular cancer [2C80] [15]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Dasatinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [69]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Dasatinib and Apixaban. Thrombosis [DB61-GB90] [15]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Dasatinib and Cangrelor. Thrombosis [DB61-GB90] [15]
Brilinta DMBR01X Major Increased risk of bleeding by the combination of Dasatinib and Brilinta. Thrombosis [DB61-GB90] [15]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Dasatinib and Lenvatinib. Thyroid cancer [2D10] [15]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Dasatinib and Cabozantinib. Thyroid cancer [2D10] [21]
Saxagliptin DMGXENV Moderate Decreased metabolism of Dasatinib caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [21]
Elagolix DMB2C0E Moderate Increased metabolism of Dasatinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [18]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Dasatinib and Betrixaban. Venous thromboembolism [BD72] [15]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Dasatinib and Valganciclovir. Virus infection [1A24-1D9Z] [18]
⏷ Show the Full List of 168 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Dasatinib 100 mg tablet 100 mg Oral Tablet Oral
Dasatinib 140 mg tablet 140 mg Oral Tablet Oral
Dasatinib 20 mg tablet 20 mg Oral Tablet Oral
Dasatinib 50 mg tablet 50 mg Oral Tablet Oral
Dasatinib 70 mg tablet 70 mg Oral Tablet Oral
Dasatinib 80 mg tablet 80 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Dasatinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5678).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
5 BDDCS applied to over 900 drugs
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
8 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
9 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
10 Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80.
11 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
12 Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39.
13 Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
14 Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008 Feb 1;111(3):1366-77. doi: 10.1182/blood-2007-04-084814. Epub 2007 Oct 25.
15 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
16 Canadian Pharmacists Association.
17 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
18 Cerner Multum, Inc. "Australian Product Information.".
19 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
20 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
21 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
23 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
24 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
25 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
26 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
27 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
28 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
29 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
30 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
31 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
32 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
33 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
34 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
35 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
36 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
37 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
38 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
39 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
40 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
41 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
42 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
43 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
44 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
45 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
46 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
47 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
48 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
49 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
50 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
51 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
52 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
53 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
54 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
55 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
56 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
57 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
58 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
59 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
60 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
61 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
62 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
64 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
65 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
66 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
67 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
68 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
69 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.